期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

西罗莫司药动学的影响因素及治疗药物监测 被引量：5

Pharmacokinetic Factors and Therapeutic Drug Monitoring of Sirolimus
下载PDF
导出
摘要 西罗莫司是一种大环内酯类抗生素,试验表明其具有较强的免疫抑制活性。目前作为一种安全性较高的免疫抑制剂,常与环孢素、激素联合使用,用于预防器官移植的排异反应。本文对西罗莫司免疫活性机制、药动学研究和临床治疗药物监测进行归纳。 Sirolimos（rapamycin） is a macrolide antibiotic.Plenty of studies suggest it has potent immunosuppressive activity.It has been used in combination with cyclosporine and steroid in the prophylaxis of acute rejection in renal transplant patients.In this review,mechanism of immunosuppression,pharmacokinetic and therapeutic drug monitoring（TDM） of sirolimus is discussed.
作者 石浩强 陈冰 许倍铭
机构地区 上海交通大学医学院附属瑞金医院药剂科
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2010年第7期543-547,共5页 Chinese Journal of Pharmaceuticals
关键词 西罗莫司 治疗药物监测 药动学 高效液相色谱 微粒子酶免疫法 sirolimus therapeutic drug monitoring pharmacokinetics HPLC microparticle enzyme immunoassay（MEIA）
分类号 R978.1 [医药卫生—药品] R969 [医药卫生—药理学]
  • 相关文献

参考文献20

  • 1Jones K,Saadat-Lajevard S,Lee T,et al.An immunoassay for the measurement of sirolimus[J].Clin Ther,2000,22Suppl B:B49-B61.
  • 2MacDonald A,Scarola J,Burke JT,et aL Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus[J].Clin Ther,2000,22 Suppl B:B101-B121.
  • 3王娟,宋洪涛,周欣,张倩.西罗莫司大鼠在体肠吸收动力学研究[J].中国药房,2009,20(1):27-30. 被引量：15
  • 4Taylor PJ,Johnson AG.Quantitative analysis of sirolimus(rapamycin)in blood by highperformance liquid chromatography-electrospray tandem mass spectrometry[J].J Chromatogr B Biomed Sci Appl,1998,718(2):251-257.
  • 5Jiao Z,Shi XJ,Li ZD,et al.Population pharmacokinetics of sirolimus in denove Chinese adult renal transplant patients[J].Br J Clin Pharmacol,2009,68(1):47-60.
  • 6朱曼,郭代红.新型大环内酯类免疫抑制剂-西罗莫司[J].中国药物应用与监测,2005,2(6):26-28. 被引量：22
  • 7Sato E,Shimomura M,Masuda S,et al.Temporal decline in sirolimus elimination immediately after pancreatic islet transplantation[J].Drug Metab Pharmacokinet,2006,21(6):492-500.
  • 8Dansirikul C,Morris RG,Tett SE,et al.A Bayesian approach for population pharmacokinetic modelling of sirolimus[J].Br J Clin Pharmacol,2006,62(4):420-434.
  • 9Podder H,Podbielski J,Hussein I,et al.Impact of sirolimus on renal transplant outcomes in African Americans[J].Transplant Proc,2001,33(1-2):1226.
  • 10Chueh SC,Wang SM,Lai MK,et al.Pharmacokinetic variability of sirolimus in Taiwan Residents renal transplant recipients[J].Transplant Proc,2004,36(7):2058-2059.

二级参考文献26

  • 1王征,樊嘉.雷帕霉素在器官移植中的研究进展[J].国外医学（移植与血液净化分册）,2004,2(5):33-35. 被引量：5
  • 2张海峰,陆晓和,袁伟.以蓖麻油为基质不同剂量雷帕霉素滴眼剂对大鼠角膜的毒性作用[J].中国组织工程研究与临床康复,2007,11(21):4101-4104. 被引量：5
  • 3Yatscoff RW, Wang P, Chan K, et al. Rapamycin distribution, pharmacokinetics and therapeutic range in- vestigations[J ]. Ther Drug Monit, 1995,17(6) :666.
  • 4Kahan BD, Podbielski J, Napodi KL, et al. Immu nosuppressive effects and safety of a sirolimus/ cy closporine combination regimen for renal transplantation [J ] . Transplantation, 1998,66(8) :1 040.
  • 5[4]Chung J,Kuo CJ,Crabtree GR,et al.Rapamyein-FkBP specifically blocks growth dependent activation of and signaling by the 70 kd s6 protein kinases[J].Cell,1992,69:1227.
  • 6[5]Dumont FJ,Su O.Mechanism of action of the immunosup-pres sant rapamycin[J].Life Sci,1996,58:373.
  • 7[7]Zimmerman JJ,Kahan BD.Pharmacokinetics of sirolimus in sta ble renal transplant patients after multiple oral dose adminis tration[J].J Clin Pharmacol,1997,37:405.
  • 8[8]Ferron GM,Mishina EV,Zimerman JJ,et al.Population pharma cokinetics of sirolimus in kidney transplant patients[J].Clin Pharmacol Ther,1997,61:416.
  • 9[15]Yatscoff RW,Wang P,Chan K,et al.Rapamycin:distribution,pharmacokinetics,and therapeutic range investigations[J].Ther Drug Monit,1995,17 (6):666.
  • 10[16]Kahan BD,Podbielski J,Napoli KL,et al.Immunosuppressive ef fects and safety of a sirolimus/cyclosporine combination regi men for renal transplantation[J].Transplantation,1998,66 (8):1040.

共引文献34

同被引文献68

  • 1王长希,尚文俊,陈立中,费继光,任斌,黎曙霞,郑克立,唐孝达,范昱,闵志廉,齐隽,黎磊石,刘志红,季曙明.肾移植受者应用西罗莫司治疗窗的临床研究[J].中国新药与临床杂志,2005,24(1):41-45. 被引量：21
  • 2焦正,杨洁,张明,施孝金.高效液相色谱法测定人血浆中咪唑立宾的浓度[J].中国新药与临床杂志,2006,25(7):489-491. 被引量：10
  • 3肖力,任斌,陈小陆.荧光偏振法测定去甲万古霉素血药浓度[J].齐齐哈尔医学院学报,2007,28(3):315-316. 被引量：9
  • 4Vignot S, Faivre S, Aguirre D, et al. mTOR-targeted therapy of cancer with rapamycin derivatives[J]. Ann Oncol, 2005,16(4) : 525.
  • 5Soliman GA. The mamme,lian target of rapamycin signaling network and gene regulation[J]. Curr Opin Lipidol, 2005,16(3) :317.
  • 6Goren S, Karahoca A, Onat FY, et al. Prediction of cyclosporine A blood levels: an application of the adaptive-net- work-based fuzzy inference system (ANFIS) in assisting drug therapy[J]. Eur J Clin Pharmacol, 2008,64 (8) : 807.
  • 7Sheiner LB, Beal SL. Some suggestions for measuring predictive performance[J]. J Pharmacokinet Biopharm,1981,9(4):503.
  • 8Jiao Z, Shi X J, Li ZD, et al. Population phannacokinetics of sirolimus in de novo Chinese adult renal transplant patients[J]. Br J Clin Pharmacol, 2009,68( 1 ) : 47.
  • 9Oellerich M, Hon, Armstrong VW. The role of therapeutic drug monitoring in individualizing immunosuppressive drug therapy: recent developments [ J ]. Ther Drug Monit, 2006,28(6) :720-725.
  • 10Khoschsorur G, Fruehwirth F, Zelzer S, et al. comparison of fluorescent polarization immunoassay ( FPIA ) versus HPLC to measure everolimus blood concentrations in clin- ical transplantation [ J ]. Clin Chim Acta, 2007,380 ( 1/ 2) :217-221.

引证文献5

二级引证文献20

中国医药工业杂志
2010年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部